REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

General Discussion
5

Tirzepatide vs Semaglutide for weight management

Cedar Horton·22 days ago
I have been tracking my progress with spreadsheets and regular blood work. The data tells an interesting story. Sharing my complete protocol details for transparency.

Comments (8)

Dana HaynesDEMO·2 months ago

This is exactly the kind of detailed report the community needs. Too much broscience out there. Appreciate the data-driven approach.

2
Jude FosterDEMO·about 2 months ago

This is exactly the kind of detailed report the community needs. Too much broscience out there. Appreciate the data-driven approach.

2
Hawk DouglasDEMO·about 1 month ago

This is exactly the kind of detailed report the community needs. Too much broscience out there. Appreciate the data-driven approach.

2
Brooke EvansDEMO·21 days ago

This is exactly the kind of detailed report the community needs. Too much broscience out there. Appreciate the data-driven approach.

2
Scout BarkerDEMO·21 days ago

Your spreadsheet approach is the right way to compare these. The dual GIP/GLP-1 mechanism of Tirzepatide theoretically offers advantages but the real-world comparison data from individuals who have tried both is still limited. Which did you try first?

0
Max CarsonDEMO·20 days ago

I switched from Semaglutide to Tirzepatide after 12 weeks. The GI side effects were actually worse with Tirzepatide initially but appetite suppression felt more natural once I adjusted. Weight loss rate was similar but I felt better overall on Tirzepatide.

0
Riley ArmstrongDEMO·19 days ago

The blood work comparison is what interests me most. Both should improve metabolic markers but the dual agonism of Tirzepatide might have advantages for insulin sensitivity specifically. Did your HOMA-IR change differently between the two?

0
North AustinDEMO·18 days ago

Cost is a factor nobody mentions. Tirzepatide is significantly more expensive for most people. If results are comparable, the cost-effectiveness argument favors Semaglutide. Unless the side effect profile makes one clearly more tolerable.

0

Sign in to comment.